Duality Biotherapeutics
Duality Biotherapeutics Inc, operating as DualityBio, is a clinical-stage biopharmaceutical enterprise focused on discovering and developing antibody-drug conjugates (ADCs) for cancer patients. The company utilizes its proprietary DDBiotech ADC technology platforms to engineer targeted therapeutics combining monoclonal antibodies with cytotoxic payloads. Revenue is primarily generated through research collaboration upfront payments, licensing option fees, and development milestone payments from global pharmaceutical partners like BioNTech. Core end markets encompass medical oncology clinics, clinical trial hospitals, and global biopharmaceutical developers. DualityBio holds an innovative position in the global oncology sector as a specialized developer of next-generation antibody-drug conjugate drug candidates. The company is headquartered in Shanghai, China, operating with global clinical trial teams in the United States.
3 of the funds FundTelligence covers report a position in Duality Biotherapeutics.
- Legal name
- Duality Biotherapeutics Inc
- Sector
- Health Care
- Country
- China
- Funds holding it
- 3
Funds holding Duality Biotherapeutics
- Handelsbanken Emerging Markets Index — Handelsbanken · 0.01 % (full portfolio disclosed, September 2026)
- Handelsbanken Global Index Criteria — Handelsbanken · 0.0 % (full portfolio disclosed, September 2026)
- BlackRock iShares MSCI EM IMI Screened UCITS ETF — BlackRock · 0.0 % (full portfolio disclosed, October 2026)